- Home
- TCI vs CRDF Comparison
TCI vs CRDF Comparison
Compare TCI & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCI
- CRDF
- Stock Information
- Founded
- TCI 1983
- CRDF 1999
- Country
- TCI United States
- CRDF United States
- Employees
- TCI N/A
- CRDF N/A
- Industry
- TCI Real Estate
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TCI Finance
- CRDF Health Care
- Exchange
- TCI Nasdaq
- CRDF Nasdaq
- Market Cap
- TCI 239.1M
- CRDF 233.5M
- IPO Year
- TCI N/A
- CRDF N/A
- Fundamental
- Price
- TCI $40.27
- CRDF $4.37
- Analyst Decision
- TCI
- CRDF Strong Buy
- Analyst Count
- TCI 0
- CRDF 6
- Target Price
- TCI N/A
- CRDF $11.92
- AVG Volume (30 Days)
- TCI 6.9K
- CRDF 1.3M
- Earning Date
- TCI 08-07-2025
- CRDF 08-07-2025
- Dividend Yield
- TCI N/A
- CRDF N/A
- EPS Growth
- TCI 59.61
- CRDF N/A
- EPS
- TCI 0.92
- CRDF N/A
- Revenue
- TCI $47,452,000.00
- CRDF $587,000.00
- Revenue This Year
- TCI N/A
- CRDF N/A
- Revenue Next Year
- TCI N/A
- CRDF N/A
- P/E Ratio
- TCI $45.33
- CRDF N/A
- Revenue Growth
- TCI N/A
- CRDF N/A
- 52 Week Low
- TCI $25.50
- CRDF $2.01
- 52 Week High
- TCI $46.74
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- TCI 47.78
- CRDF 72.91
- Support Level
- TCI $41.59
- CRDF $3.07
- Resistance Level
- TCI $42.75
- CRDF $4.55
- Average True Range (ATR)
- TCI 1.10
- CRDF 0.22
- MACD
- TCI -0.68
- CRDF 0.08
- Stochastic Oscillator
- TCI -5.62
- CRDF 94.59
About TCI Transcontinental Realty Investors Inc.
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.